Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 148
News
News | 11 January 2022

Prof. Jason Kovacic bags Agilent Thought Leader award

Victor Chang Cardiac Research Institute (VCCRI) researcher recognized for his influential work on cardiovascular disease

News
News | 11 January 2022

Molnupiravir best option to treat Covid-19 now: Experts

Health experts of the country have pointed out that the benefits of the drug outweigh the potential risks it may have in the case of high-risk patients

News
News | 11 January 2022

Aurobindo’s CuraTeQ and Orion expand licencing deal in select European markets

CuraTeQ and Orion had entered into a licensing agreement, granting marketing and distribution rights for CuraTeQ’s biosimilar products under development in the Nordic states, Austria, Hungary and Slovenia

News
News | 10 January 2022

Arch Pharmalabs signs agreement with Orchem Technologies to use SMB platform

Simulated Moving Bed (SMB) technology is a highly engineered process for implementing chromatographic separation

News
News | 10 January 2022

Clarivate identifies seven potential blockbuster drugs in Annual Drugs to Watch report

Despite the challenges of pandemic disruptions, drug developers advance promising therapies for conditions, including Alzheimer's, diabetes and asthma

News
News | 08 January 2022

Covaxin booster dose study shows promising results

Six months after receipt of the second Covaxin dose, participants received booster dose of the same. The trial demonstrated long-term safety with no serious events

News
News | 08 January 2022

Moderna Covid-19 boosters after five-month interval: U.S. FDA

Earlier last week the U.S. FDA had also shortened the time to receive a Pfizer booster shot from six months to five months for everyone 12 and older

News
News | 07 January 2022

Lupin launches Molnulup to treat Covid-19

The drug is priced at Rs 2000 for a course of 40 tablets

News
News | 06 January 2022

Aurobindo Pharma rolls out Molnaflu in India

The brand is now available pan-India through their distribution partner

News
News | 06 January 2022

Margins under pressure; domestic market growth to slow down: Nirmal Bang

A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies

News
News | 06 January 2022

ENTOD Pharmaceuticals set to launch Molentod

It is the generic version of molnupiravir

News
News | 05 January 2022

Bharat Biotech's intranasal vaccine Phase 3 trials gets approval

It has also been granted permission to conduct trials for booster dose

News
News | 04 January 2022

Combination of Covishield-Covaxin more effective: AIG hospital study

The first pilot study from India analyzing Covaxin-Covishield mixed doses

News
News | 04 January 2022

Domestic and emerging markets will drive pharma growth: ICRA

Healthy growth in domestic and emerging markets is expected to support revenue growth in the next few quarters

News
News | 04 January 2022

Dr Reddy’s molnupiravir priced at Rs 1,400 for a course

Molflu is expected to be available from early next week in pharmacies throughout the country with a particular focus on states with a high caseload of Covid-19.

News
News | 03 January 2022

U.S. FDA grants EUA for Pfizer-BioNTech booster for 12 years and older

First emergency use authorization in the United States for a Covid-19 vaccine booster in adolescents 12 through 15 years of age

News
News | 30 December 2021

Biological E gets nod to study Corbevax as a booster dose

The Subject Expert Committee has recommended grant of permission to conduct Phase 3 trials under certain conditions

News
News | 30 December 2021

Green ChemisTree Foundation announces virtual conference on Innovations in Green & Sustainable Chemistry for Pharma Industry

Aim of the virtual conference is to facilitate Indian Pharma Industry adopt Green & Sustainable Chemistry as a tool to enhance Economic & Environmental Competitiveness

News
News | 30 December 2021

Sanofi loses appeal in the US over Lantus device patents

Decisions reaffirm the ability of Biocon Biologics and Viatris to provide patient access to interchangeable Semglee

News
News | 30 December 2021

Study demonstrates Covaxin safe for kids in the age 2-18 years

Covaxin has proven to be safe, well-tolerated, and immunogenic in paediatric subjects in phase II/III study. Neutralizing antibodies in children on an average 1.7 times higher than in adults

Startup

Digitization